Trials

This is a brief summary of Clinical Trials coordinated by Michelangelo Tech

Trials

This is a brief summary of Clinical Trials coordinated by Michelangelo Tech

An adaptive first-in-human trial of PhOx430, a first-in-class acetylglucosaminyltransferase V inhibitor, in patients with Advanced Solid Tumours (PhAST Trial)

Sponsor: Phost’In Therapeutics SAS
Design: Phase I (First-in-Human), multicenter, international study
Indication: Adult patients with advanced or metastatic solid malignancies with radiologically documented progression on a previous line of treatment and for which effective treatment options do not exist
EU Countries: Italy, France

Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer – APTneo

Sponsor: Fondazione Michelangelo Onlus
Design: Phase III, randomized, multicenter, international study
Indication: women with a diagnosis of early high-risk invasive unilateral, HER2-positive breast cancer suitable for neoadjuvant therapy
Conduct: this multicenter trial is conducted under the sponsorship and overall trial oversight of the Fondazione Michelangelo, and conducted in collaboration with regional European and non-European research groups and other sites.
EU Countries: Italy, Germany, Austria, Belgium, Spain, Romania
Non-EU Countries: Taiwan

Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative, Early High-Risk and Locally Advanced Breast Cancer undergoing treatment with nab-paclitaxel and carboplatin NeoTRIPaPDL1 (Neoadjuvant therapy in TRIPle negative breast cancer with antiPDL1)

Sponsor: Fondazione Michelangelo Onlus
Design: Phase III, randomized, multicenter, international study
Indication: Women with a diagnosis of invasive unilateral early high-risk and locally advanced or inflammatory, triple negative (HER2-negative and ERnegative and PgR-negative) breast cancer of high proliferation or grade suitable for neoadjuvant therapy
Conduct: this multicenter trial is conducted under the sponsorship and overall trial oversight of the Fondazione Michelangelo, and conducted in collaboration with regional European and non-European participating research groups and other sites.
EU Countries: Italy, Germany, Austria, Spain, Ireland
Non-EU Countries: Russia, Taiwan

Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2- negative high-risk breast cancer - ETNA (Evaluating Treatment with Neoadjuvant Abraxane)

Sponsor: Fondazione Michelangelo Onlus
Design: Phase III, randomized, multicenter, international study
Indication: Patients with HER2-negative, non metastatic unilateral breast cancer who are at risk of disease recurrence and suitable for neoadjuvant chemotherapy
Conduct: this multicenter trial is conducted under the sponsorship and overall trial oversight of the Fondazione Michelangelo, and conducted in collaboration with regional European and non-European research groups and other sites.
EU Countries: Italy, Germany, Austria, Spain
Non-EU Countries: Russia, Singapore, Australia

Neo-Adjuvant Treatment with the CDK4,6 inhibitor Palbociclib in HER2- positive and ER-positive breast cancer: effect on Ki67 and apoptosis before, during and after treatment - NA-PHER2

Sponsor: Fondazione Michelangelo Onlus
Design: Exploratory Phase II with parallel cohorts
Indication: Women with a diagnosis of invasive unilateral non metastatic ERpositive
breast cancer expressing HER2 and suitable for neoadjuvant therapy
Conduct: this multicenter trial was conducted under the sponsorship and overall trial oversight of the Fondazione Michelangelo in Italy

For information about Trials results, please contact Michelangelo Tech.

For information about Trials results, please contact Michelangelo Tech.